Third Party Manufacturing – Dasatinib Tablets 50 mg

Medizia Biotech offers Third Party Manufacturing of Dasatinib Tablets 50 mg with a commitment to quality, regulatory compliance, and timely delivery. Manufactured in WHO-GMP certified facilities, our Dasatinib tablets meet stringent pharmaceutical quality standards to ensure safety, efficacy, and consistency. We provide comprehensive contract manufacturing solutions for pharmaceutical companies, distributors, hospitals, government tenders, and healthcare organizations looking to expand their oncology product portfolio.

Dasatinib 50 mg Tablets are widely prescribed for the treatment of Philadelphia chromosome-positive (Ph+) Chronic Myeloid Leukemia (CML) and Acute Lymphoblastic Leukemia (ALL). As a trusted third-party manufacturing partner, Medizia Biotech offers high-quality formulations with advanced manufacturing processes, ensuring reliable product performance and international quality standards.

Our third-party manufacturing services include:

• WHO-GMP compliant manufacturing facilities
• Custom branding and private labeling
• Attractive and premium packaging solutions
• Flexible batch sizes with low MOQ options
• Bulk manufacturing and institutional supply
• Regulatory documentation support
• On-time production and nationwide delivery
• Competitive pricing with consistent quality assurance

Whether you are launching a new oncology brand or expanding your existing product portfolio, Medizia Biotech provides complete third-party manufacturing support for Dasatinib Tablets 50 mg. Our experienced team ensures every batch undergoes rigorous quality control and complies with applicable pharmaceutical manufacturing standards.

Partner with Medizia Biotech for reliable Dasatinib Tablets 50 mg Third Party Manufacturing and benefit from superior quality, dependable supply, customized packaging, and professional manufacturing services designed to help grow your pharmaceutical business.